Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZA-AEGEAN: Neoadjuvant Inhaled Azacytidine + Chemo-Immunotherapy for Early-Stage NSCLC
NCT06694454Phase 2Suspended
- Sponsor
- National Cancer Institute
- Start
- Nov 2026
- Primary completion
- Dec 2031
- Countries
- 1
01
Overview
Phase 2, open-label trial of azacitidine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose, Recommended Phase II Dose and 1 more. Started Nov 2026; status: suspended.
02
Drugs
azacitidine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06694454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06694454.